SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as community members aggressively debate its potential for massive gains versus risks of a rug pull, with many investors actively rotating profits into competing projects like MAULCOIN. The conversation is dominated by high-energy shilling and speculation about whether the token can shed more zeros or if it is merely another volatile pump-and-dump scheme.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining momentum as the developer actively engages the community with daily airdrops and plans for a dedicated website, fueling sentiment that the current low market cap offers an early entry point. Community members are actively debating the project's resilience following initial volatility, with many highlighting locked liquidity and the anticipation of official chart integration as key catalysts for potential growth.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following a media report that GameStop is building a stake in the company as part of a potential takeover strategy, fueling speculation about a high-stakes e-commerce merger. Community sentiment is deeply divided, with many traders expressing skepticism about the financial feasibility of such a deal while others debate the potential strategic value of integrating collectibles and retail operations.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing significant community attention and speculative interest as traders anticipate a major supply reduction driven by upcoming burn events. The discussion centers on long-term conviction, with many participants debating the potential for a price recovery and debating the merits of supporting active on-chain projects to foster ecosystem growth.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MULN symbol is generating significant activity on social forums, with many users debating its transition from a struggling EV stock to a speculative crypto project, while community members aggressively promote various low-cap meme coins using the ticker as a rallying point. Investors remain deeply divided, with one side highlighting the potential for volatile price swings often associated with these meme-driven plays, while skeptical participants warn of historical patterns of dilution and recurring scams.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grumman is trending as investors react to a significant push for increased military spending and potential contract wins, while community discussions focus on its stable backlog and critical role in major defense programs like the B-21 Raider. Sentiment remains heavily influenced by geopolitical tensions and expectations for sustained defense sector growth.

Baby Doge Coin is a meme cryptocurrency designed to be deflationary and more scarce over time. All holders of Baby Doge will earn more baby doge that is automatically sent to your wallet by simply holding Baby Doge coins in your wallet. Watch the amount of baby doge grow in your wallet as baby doge coin holders automatically receive a 5% fee from every on chain transaction that happens on the Baby Doge ecosystem. The community receives more baby doge coins from the fees generated each transaction.

Baby Doge Coin

Baby Doge Coin is experiencing significant community momentum and social buzz as holders speculate on potential upcoming listings on major U.S. exchanges. Investors are actively discussing the coin's resilience during market corrections while debating strategies for accumulating positions in anticipation of a broader meme coin cycle.

Hamilton Insurance Group Ltd. is a holding company, which provides insurance and reinsurance services. It operates through the International and Bermuda segments. The International segment comprises of property, specialty, and casualty insurance and reinsurance classes of business originating from the company's London, Dublin, and Hamilton Select operations. The Bermuda segment offers property, specialty, and casualty insurance and reinsurance classes of business originating from Hamilton Re, Bermuda and Hamilton Re US and subsidiaries. The company was founded in 2013 and is headquartered in Hamilton, Bermuda.

Hamilton Insurance Group Ltd. - Ordinary Shares - Class B

Hamilton Insurance Group is trending as investors analyze its recent earnings performance and market valuation relative to its book value, while the community simultaneously discusses the growth potential and technological breakthroughs of HydroGraph Clean Power, often mentioned alongside the same ticker symbol. Traders are actively debating the company's insurance-focused fundamentals versus the high-growth narrative surrounding its graphene-tech association.

Sperax is redefining financial autonomy through programmable agents that manage capital, optimize yield, and protect against risk, all transparently on-chain. Founded in 2019, Sperax is backed by leading investors including Jump Trading, Polychain Capital, Amber Group. Sperax offers a new standard in automated, user-driven finance.  The SperaxOS ecosystem is powered by USDs and SPA on Arbitrum, BNB Chain, and other EVM networks. Anchored by two native assets: USDs, a gas-free, auto-yield stablecoin backed by on-chain collateral, and SPA, the governance and value-capture token. Sperax builds open-source tools that turn idle capital into self-optimizing portfolios.  SperaxOS is a cross-chain financial operating system where AI-driven smart agents automate everything from yield farming to payroll, and Demeter, a no-code platform for launching liquidity farms. USDs automatically rebases yield to holders, while SPA lets users register agents, earn protocol fees, and vote on upgrades. Battle-tested through multiple market cycles: Sperax offers individuals, DAOs, and fintechs a borderless toolkit for passive income, risk-managed investing, and fully automated treasury operations, all governed on-chain by its community.

Sperax

Sperax (SPA) is trending as community members point to the recent launch of SperaxOS, increased trading volume, and anticipation surrounding stablecoin legislation and potential future exchange listings. Long-term holders are actively accumulating the token, expressing optimism that the project's DeFi utility and AI-powered yield mechanisms will drive a significant price breakout.

PayPal USD is designed to contribute to the opportunity stablecoins offer for payments and is 100% backed by U.S. dollar deposits, short-term U.S Treasuries and similar cash equivalents. PayPal USD is redeemable 1:1 for U.S. dollars and is issued by Paxos Trust Company.

PayPal USD

PayPal USD is generating significant attention as the community weighs its cross-border expansion and integration into diverse blockchain ecosystems against ongoing legislative debates surrounding stablecoin regulation. Investors are actively discussing the potential impact of federal oversight on the stablecoin market while tracking its adoption rates across various decentralized finance platforms.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arvinas (NASDAQ:ARVN) Shares Up 9.9%  - What's Next?

Arvinas (NASDAQ:ARVN) Shares Up 9.9% - Time to Buy...

<ul class="summary-bullets"><li>The decision also marks the FDA’s first approval of a PROTAC therapy, a type of targeted protein-degrading drug.</li><li>The approval is based on a Phase 3 trial, in which Veppanu reduced the risk of disease progression or death by 43% compared with Fulvestrant.</li><li>Arvinas and Pfizer plan to partner with a third party to support the drug’s commercial rollout.</li></ul>Shares of Arvinas Inc. (ARVN) gained nearly 10% on Friday, after the company announced that the U.S. Food and Drug Administration approved its breast cancer drug to treat patients with ES1 mutations.The drug, Vepdegestrant, which will be marketed as Veppanu, was jointly developed with Pfizer (PFE). The approval comes more than a month ahead of the Prescription Drug User Fee Act (PDUFA) action date.The decision also marks the FDA’s first approval of a Proteolysis Targeting Chimera (PROTAC) therapy, a type of targeted protein-degrading drug.<h2 class="st-heading-2">Disease Progression Reduced By 43%</h2>The approval is based on a Phase 3 trial, in which Veppanu reduced the risk of disease progression or death by 43% compared with Fulvestrant, an injection for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Median progression-free survival improved to five months versus 2.1 months.Arvinas and Pfizer plan to partner with a third party to support the drug’s commercial rollout.“We are especially encouraged by receiving FDA approval ahead of the June 5 PDUFA date, and together with Pfizer, we are on track to announce selection of a third party to bring this new treatment option to patients as soon as possible,” said Randy Teel, President and CEO at Arvinas.The drug received Fast Track designation from the FDA in 2024, followed by the agency’s acceptance of its New Drug Application (NDA) for review last August.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/ARVN">ARVN</a> on Stocktwits remained in the ‘bullish’ territory over the past 24 hours, amid ‘high’ message volumes.One user sees the stock as a “long-term hold.”<stembedurl>https://stocktwits.com/Regulator06/message/652035353</stembedurl>The stock has declined 11% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/sobr-stock-merger-/cZQVaFFReeS">This Nanocap Stock Surged More Than 100% After A Strategic Pivot To Tap Into AI Data Center Market – Retail Bulls See Bigger Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arvinas logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule

The FDA approved Veppanu on Friday, which was jointly developed by Pfizer and the company.

Equity

Arvinas (ARVN) Expected to Announce Earnings on Thursday

Arvinas (NASDAQ:ARVN) will be releasing its Q1 2026 earnings before the market opens on Thursday, April 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-30-arvinas-inc-stock...

Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Hold" from Analysts

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) has been given an average rating of "Hold" by the nineteen research firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts...

JPMorgan Chase & Co. Has $1.83 Million Stock Holdings in Arvinas, Inc. $ARVN

JPMorgan Chase & Co. lifted its holdings in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 475.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 214,779 shares of the company's stock after buying an additional 1...

Arvinas (NASDAQ:ARVN)  Shares Down 5.1%   - Time to Sell?

Arvinas (NASDAQ:ARVN) Shares Down 5.1% - Should You Sell...

Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?

Arvinas (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of "Hold" from Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) have been assigned an average recommendation of "Hold" from the nineteen research firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, seven have assigned...

Arvinas (NASDAQ:ARVN) Insider Sells $71,428.50 in Stock

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) insider Noah Berkowitz sold 6,435 shares of the business's stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of...

Noah Berkowitz Sells 6,435 Shares of Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) insider Noah Berkowitz sold 6,435 shares of the stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $11.10, for a total value of $71,428.50. Following the transaction, the insider owned 202,503 shares...

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

ARVN
Arvinas Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ARVN News

ARVNArvinas Inc